The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.

ASCO 2025
Abstracts Supported by Bayer
May 30- June 3, 2025

Agenda of oral and poster presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Please see below to download a PDF for each presentation and view a video (where applicable). Access for each publication will be available after the congress presentation. 

Please select a compound to navigate to all related publications.

 

 

 

    ALL

    DAROLUTAMIDE

    Health-related quality of life (HRQoL) outcomes with darolutamide in the phase 3 ARANOTE trial
    Date/Time:
    Tuesday, June 3, 2025 | 10:57 AM – 11:09 PM CDT
    Session:
    Genitourinary Cancer—Prostate, Testicular, and Penile
    Type:
    Oral Abstract Session
    Presenting Author:
    Alicia K. Morgans
    Abstract Number #:
    5004
    Download the presentation View the Video
    Substudy C of the Canadian cancer trials group (CCTG) IND.234: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)—A phase II study of darolutamide (DARO) selected by androgen-receptor (AR) circulating tumor DNA (ctDNA) in patients (PTS) with metastatic castration-resistant prostate cancer (mCRPC) after prior AR pathway inhibitors (ARPIs)
    Date/Time:
    Monday, June 2, 2025 | 9:00 AM – 12:00 PM CDT
    Session:
    Genitourinary Cancer—Prostate, Testicular, and Penile
    Type:
    Poster Session
    Presenting Author:
    Michael Ong
    Poster Board Number #:
    255
    Download the poster
    Darolutamide plus androgen deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP)
    Date/Time:
    Monday, June 2, 2025 | 9:00 AM – 12:00 PM CDT
    Session:
    Genitourinary Cancer—Prostate, Testicular, and Penile
    Type:
    Poster Session
    Presenting Author:
    Alicia K. Morgans
    Poster Board Number #:
    319B
    Download the poster View the Video
    Prognostic significance of PSA>0.2 after 6-12 months treatment for metastatic hormone-sensitive prostate cancer (mHSPC) intensified by androgen-receptor pathway inhibitors (ARPI): A multinational real-world analysis of the IRONMAN registry
    Date/Time:
    Tuesday, June 3, 2025 | 10:33 AM – 10:45 PM CDT
    Session:
    Genitourinary Cancer—Prostate, Testicular, and Penile
    Type:
    Oral Abstract Session
    Presenting Author:
    Michael Ong
    Abstract Number #:
    5002
    Download the presentation

    LAROTRECTINIB

    Efficacy and safety of larotrectinib in patients with TRK fusion lung cancer: An updated analysis
    Date/Time:
    Saturday, May 31, 2025 | 1:30 PM – 4:30 PM CDT
    Session:
    Lung Cancer—Non-Small Cell Metastatic
    Type:
    Poster Session
    Presenting Author:
    Daniel S-W Tan
    Poster Board Number #:
    90
    Download the poster
    Efficacy and safety of larotrectinib in patients with TRK fusion thyroid carcinoma: An updated analysis
    Date/Time:
    Monday, June 2, 2025 | 9:00 AM – 12:00 PM CDT
    Session:
    Head and Neck Cancer
    Type:
    Poster Session
    Presenting Author:
    Marcia S. Brose
    Poster Board Number #:
    502
    Download the poster View the Video
    Larotrectinib resistance in TRK fusion cancers: Analysis of a tumor-agnostic, global clinical trial dataset
    Date/Time:
    Monday, June 2, 2025 | 1:30 PM – 4:30 PM CDT
    Session:
    Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
    Type:
    Poster Session
    Presenting Author:
    Alexander E Drilon
    Poster Board Number #:
    381
    Download the poster View the Video
    Efficacy and safety of larotrectinib in patients with non-primary central nervous system TRK fusion cancer: An updated analysis
    Date/Time:
    Monday, June 2, 2025 | 1:30 PM – 4:30 PM CDT
    Session:
    Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
    Type:
    Poster Session
    Presenting Author:
    Rui-Hua Xu
    Poster Board Number #:
    463
    Download the poster View the Video

    RADIUM-223

    A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis
    Date/Time:
    Tuesday, June 3, 2025 | 11:57 AM – 12:09 PM CDT
    Session:
    Genitourinary Cancer—Prostate, Testicular, and Penile
    Session Type:
    Oral Abstract Session
    Presenting Author:
    Rana R. McKay
    Abstract Number #:
    5007
    Download the presentation
    Long-term safety of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC): 7-year follow-up from the largest global prospective study
    Date/Time:
    Monday, June 2, 2025 | 9:00 AM – 12:00 PM CDT
    Session:
    Genitourinary Cancer—Prostate, Testicular, and Penile
    Type:
    Poster Session
    Presenting Author:
    Alton Oliver Sartor
    Poster Board Number #:
    247
    Download the poster
    PSA and alkaline phosphatase changes in the EORTC-1333 PEACE-3 study evaluating the addition of six cycles of radium 223 in metastatic castration-resistant prostate cancer (mCRPC) starting enzalutamide
    Date/Time:
    Monday, June 2, 2025 | 9:00 AM – 12:00 PM CDT
    Session:
    Genitourinary Cancer—Prostate, Testicular, and Penile
    Type:
    Poster Session
    Presenting Author:
    Andrey Soares
    Poster Board Number #:
    261
    Download the poster
    The impact of DNA repair genetic alterations identified by circulating tumor DNA on sensitivity to radium-223 in bone metastatic, castration-resistant prostate cancer
    Date/Time:
    Monday, June 2, 2025 | 9:00 AM – 12:00 PM CDT
    Session:
    Genitourinary Cancer—Prostate, Testicular, and Penile
    Type:
    Poster Session
    Presenting Author:
    Steven M. Blinka
    Poster Board Number #:
    314A
    Download the poster
    A phase l and randomized phase ll trial of radium-223 dichloride, peposertib, and avelumab in advanced metastatic castrate-resistant prostate cancer (mCRPC): Phase l results
    Date/Time:
    Monday, June 2, 2025 | 9:00 AM – 12:00 PM CDT
    Session:
    Genitourinary Cancer—Prostate, Testicular, and Penile
    Type:
    Poster Session
    Presenting Author:
    Hiram Alberto Gay
    Poster Board Number #:
    268
    Download the poster

    TKI

    Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA (ctDNA): Results of the phase II randomized PARERE trial by GONO
    Date/Time:
    Sunday, June 1, 2025 | 12:00 PM – 12:06 PM CDT
    Session:
    Gastrointestinal Cancer—Colorectal and Anal
    Session Type:
    Rapid Oral Abstract Session
    Presenting Author:
    Chiara Cremolini
    Abstract Number #:
    LBA3515
    Download the presentation
    Phase Ib study of the combination of regorafenib with conventional chemotherapy in patients with newly diagnosed multi-metastatic Ewing sarcoma: The Rego-Inter-Ewing-1 study
    Date/Time:
    Saturday, May 31, 2025 | 5:24 PM – 5:36 PM CDT
    Session:
    Pediatric Oncology I
    Session Type:
    Oral Abstract Session
    Presenting Author:
    Pablo Berlanga
    Abstract Number #:
    10008
    Download the presentation
    A phase 1, first-in-human study of regorafenib plus temozolomide with or without radiotherapy in patients with newly diagnosed MGMT methylated, IDHwt glioblastoma: The REGOMA-2 trial
    Date/Time:
    Saturday, May 31, 2025 | 9:00 AM – 12:00 PM CDT
    Session:
    Central Nervous System Tumors
    Type:
    Poster Session
    Presenting Author:
    Marta Padovan
    Poster Board Number #:
    114
    Download the poster
    Evaluation of the combination of regorafenib + avelumab in patients with non-small cell lung cancer without oncogenic addiction: The phase II REGOMUNE study
    Date/Time:
    Saturday, May 31, 2025 | 1:30 PM – 4:30 PM CDT
    Session:
    Lung Cancer—Non-Small Cell Metastatic
    Type:
    Poster Session
    Presenting Author:
    Sophie Cousin
    Poster Board Number #:
    29
    Download the poster
    Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: The MIRAGE trial
    Date/Time:
    Saturday, May 31, 2025 | 9:00 AM – 12:00 PM CDT
    Session:
    Central Nervous System Tumors
    Type:
    Poster Session
    Presenting Author:
    Giuseppe Lombardi
    Poster Board Number #:
    141A
    Download the poster
    Combining low-dose regorafenib with pembrolizumab as a front-line therapy for patients with MSI-H colorectal cancer: REGPEM-CRC-01
    Date/Time:
    Saturday, May 31, 2025 | 9:00 AM – 12:00 PM CDT
    Session:
    Gastrointestinal Cancer—Colorectal and Anal
    Type:
    Poster Session
    Presenting Author:
    Ibrahim Halil Sahin
    Poster Board Number #:
    307A
    Download the poster
    Myeloablative fractionated busulfan conditioning regimen with sorafenib for allogeneic stem cell transplant in AML: Results of a phase 1/2 study
    Date/Time:
    Sunday, June 1, 2025 | 9:00 AM – 12:00 PM CDT
    Session:
    Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
    Type:
    Poster Session
    Presenting Author:
    Uday Popat
    Poster Board Number #:
    177
    Download the poster
    Combined RAF- and MEK-inhibition in solid cancers with kinase-impaired BRAF mutations (SORATRAM phase I trial)
    Date/Time:
    Monday June 2, 2025 | 1:30 PM – 4:30 PM CDT
    Session:
    Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
    Type:
    Poster Session
    Presenting Author:
    Anna Lena Illert
    Poster Board Number #:
    434
    Download the poster
    Evaluation of longitudinal image-derived AI prognostication as a predictor of overall survival (OS) in a phase 3 advanced non-small cell lung cancer (aNSCLC) trial
    Date/Time:
    Sunday, June 1, 2025 | 9:00 AM – 12:00 PM CDT
    Session:
    Care Delivery/Models of Care
    Type:
    Poster Session
    Presenting Author:
    Omar Farooq Khan
    Poster Board Number #:
    318
    Download the poster

    BAY 2927088

    SOHO-01: Safety and efficacy of BAY 2927088 in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC) who were pretreated but naïve to HER2-targeted therapy or had not received any treatment for advanced disease
    Date/Time:
    Sunday, June 1, 2025 | 9:12 AM – 9:24 AM CDT
    Session:
    Lung Cancer—Non-Small Cell Metastatic
    Session Type:
    Oral Abstract Session
    Presenting Author:
    Herbert H. Loong
    Abstract Number #:
    8504
    Download the presentation
    panSOHO: Phase II trial of BAY 2927088 in patients with unresectable or metastatic solid tumors other than NSCLC with HER2‑activating mutations
    Date/Time:
    Monday, June 2, 2025 | 1:30 PM – 4:30 PM CDT
    Session:
    Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
    Type:
    Poster Session
    Presenting Author:
    Vivek Subbiah
    Poster Board Number #:
    486A
    Download the poster
    SOHO-02: Phase III trial of BAY 2927088 in patients with locally advanced or metastatic NSCLC with HER2-activating mutations.
    Date/Time:
    Saturday, May 31, 2025 | 1:30 PM – 4:30 PM CDT
    Session:
    Lung Cancer—Non-Small Cell Metastatic
    Type:
    Poster Session
    Presenting Author:
    Xiuning Le
    Poster Board Number #:
    127B
    Download the poster
    DAROLUTAMIDE

    DAROLUTAMIDE

    Health-related quality of life (HRQoL) outcomes with darolutamide in the phase 3 ARANOTE trial
    Date/Time:
    Tuesday, June 3, 2025 | 10:57 AM – 11:09 PM CDT
    Session:
    Genitourinary Cancer—Prostate, Testicular, and Penile
    Type:
    Oral Abstract Session
    Presenting Author:
    Alicia K. Morgans
    Abstract Number #:
    5004
    Download the presentation View the Video
    Substudy C of the Canadian cancer trials group (CCTG) IND.234: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)—A phase II study of darolutamide (DARO) selected by androgen-receptor (AR) circulating tumor DNA (ctDNA) in patients (PTS) with metastatic castration-resistant prostate cancer (mCRPC) after prior AR pathway inhibitors (ARPIs)
    Date/Time:
    Monday, June 2, 2025 | 9:00 AM – 12:00 PM CDT
    Session:
    Genitourinary Cancer—Prostate, Testicular, and Penile
    Type:
    Poster Session
    Presenting Author:
    Michael Ong
    Poster Board Number #:
    255
    Download the poster
    Darolutamide plus androgen deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP)
    Date/Time:
    Monday, June 2, 2025 | 9:00 AM – 12:00 PM CDT
    Session:
    Genitourinary Cancer—Prostate, Testicular, and Penile
    Type:
    Poster Session
    Presenting Author:
    Alicia K. Morgans
    Poster Board Number #:
    319B
    Download the poster View the Video
    Prognostic significance of PSA>0.2 after 6-12 months treatment for metastatic hormone-sensitive prostate cancer (mHSPC) intensified by androgen-receptor pathway inhibitors (ARPI): A multinational real-world analysis of the IRONMAN registry
    Date/Time:
    Tuesday, June 3, 2025 | 10:33 AM – 10:45 PM CDT
    Session:
    Genitourinary Cancer—Prostate, Testicular, and Penile
    Type:
    Oral Abstract Session
    Presenting Author:
    Michael Ong
    Abstract Number #:
    5002
    Download the presentation
    LAROTRECTINIB

    LAROTRECTINIB

    Efficacy and safety of larotrectinib in patients with TRK fusion lung cancer: An updated analysis
    Date/Time:
    Saturday, May 31, 2025 | 1:30 PM – 4:30 PM CDT
    Session:
    Lung Cancer—Non-Small Cell Metastatic
    Type:
    Poster Session
    Presenting Author:
    Daniel S-W Tan
    Poster Board Number #:
    90
    Download the poster
    Efficacy and safety of larotrectinib in patients with TRK fusion thyroid carcinoma: An updated analysis
    Date/Time:
    Monday, June 2, 2025 | 9:00 AM – 12:00 PM CDT
    Session:
    Head and Neck Cancer
    Type:
    Poster Session
    Presenting Author:
    Marcia S. Brose
    Poster Board Number #:
    502
    Download the poster View the Video
    Larotrectinib resistance in TRK fusion cancers: Analysis of a tumor-agnostic, global clinical trial dataset
    Date/Time:
    Monday, June 2, 2025 | 1:30 PM – 4:30 PM CDT
    Session:
    Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
    Type:
    Poster Session
    Presenting Author:
    Alexander E Drilon
    Poster Board Number #:
    381
    Download the poster View the Video
    Efficacy and safety of larotrectinib in patients with non-primary central nervous system TRK fusion cancer: An updated analysis
    Date/Time:
    Monday, June 2, 2025 | 1:30 PM – 4:30 PM CDT
    Session:
    Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
    Type:
    Poster Session
    Presenting Author:
    Rui-Hua Xu
    Poster Board Number #:
    463
    Download the poster View the Video
    RADIUM-223

    RADIUM-223

    A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis
    Date/Time:
    Tuesday, June 3, 2025 | 11:57 AM – 12:09 PM CDT
    Session:
    Genitourinary Cancer—Prostate, Testicular, and Penile
    Session Type:
    Oral Abstract Session
    Presenting Author:
    Rana R. McKay
    Abstract Number #:
    5007
    Download the presentation
    Long-term safety of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC): 7-year follow-up from the largest global prospective study
    Date/Time:
    Monday, June 2, 2025 | 9:00 AM – 12:00 PM CDT
    Session:
    Genitourinary Cancer—Prostate, Testicular, and Penile
    Type:
    Poster Session
    Presenting Author:
    Alton Oliver Sartor
    Poster Board Number #:
    247
    Download the poster
    PSA and alkaline phosphatase changes in the EORTC-1333 PEACE-3 study evaluating the addition of six cycles of radium 223 in metastatic castration-resistant prostate cancer (mCRPC) starting enzalutamide
    Date/Time:
    Monday, June 2, 2025 | 9:00 AM – 12:00 PM CDT
    Session:
    Genitourinary Cancer—Prostate, Testicular, and Penile
    Type:
    Poster Session
    Presenting Author:
    Andrey Soares
    Poster Board Number #:
    261
    Download the poster
    The impact of DNA repair genetic alterations identified by circulating tumor DNA on sensitivity to radium-223 in bone metastatic, castration-resistant prostate cancer
    Date/Time:
    Monday, June 2, 2025 | 9:00 AM – 12:00 PM CDT
    Session:
    Genitourinary Cancer—Prostate, Testicular, and Penile
    Type:
    Poster Session
    Presenting Author:
    Steven M. Blinka
    Poster Board Number #:
    314A
    Download the poster
    A phase l and randomized phase ll trial of radium-223 dichloride, peposertib, and avelumab in advanced metastatic castrate-resistant prostate cancer (mCRPC): Phase l results
    Date/Time:
    Monday, June 2, 2025 | 9:00 AM – 12:00 PM CDT
    Session:
    Genitourinary Cancer—Prostate, Testicular, and Penile
    Type:
    Poster Session
    Presenting Author:
    Hiram Alberto Gay
    Poster Board Number #:
    268
    Download the poster
    TKI

    TKI

    Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA (ctDNA): Results of the phase II randomized PARERE trial by GONO
    Date/Time:
    Sunday, June 1, 2025 | 12:00 PM – 12:06 PM CDT
    Session:
    Gastrointestinal Cancer—Colorectal and Anal
    Session Type:
    Rapid Oral Abstract Session
    Presenting Author:
    Chiara Cremolini
    Abstract Number #:
    LBA3515
    Download the presentation
    Phase Ib study of the combination of regorafenib with conventional chemotherapy in patients with newly diagnosed multi-metastatic Ewing sarcoma: The Rego-Inter-Ewing-1 study
    Date/Time:
    Saturday, May 31, 2025 | 5:24 PM – 5:36 PM CDT
    Session:
    Pediatric Oncology I
    Session Type:
    Oral Abstract Session
    Presenting Author:
    Pablo Berlanga
    Abstract Number #:
    10008
    Download the presentation
    A phase 1, first-in-human study of regorafenib plus temozolomide with or without radiotherapy in patients with newly diagnosed MGMT methylated, IDHwt glioblastoma: The REGOMA-2 trial
    Date/Time:
    Saturday, May 31, 2025 | 9:00 AM – 12:00 PM CDT
    Session:
    Central Nervous System Tumors
    Type:
    Poster Session
    Presenting Author:
    Marta Padovan
    Poster Board Number #:
    114
    Download the poster
    Evaluation of the combination of regorafenib + avelumab in patients with non-small cell lung cancer without oncogenic addiction: The phase II REGOMUNE study
    Date/Time:
    Saturday, May 31, 2025 | 1:30 PM – 4:30 PM CDT
    Session:
    Lung Cancer—Non-Small Cell Metastatic
    Type:
    Poster Session
    Presenting Author:
    Sophie Cousin
    Poster Board Number #:
    29
    Download the poster
    Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: The MIRAGE trial
    Date/Time:
    Saturday, May 31, 2025 | 9:00 AM – 12:00 PM CDT
    Session:
    Central Nervous System Tumors
    Type:
    Poster Session
    Presenting Author:
    Giuseppe Lombardi
    Poster Board Number #:
    141A
    Download the poster
    Combining low-dose regorafenib with pembrolizumab as a front-line therapy for patients with MSI-H colorectal cancer: REGPEM-CRC-01
    Date/Time:
    Saturday, May 31, 2025 | 9:00 AM – 12:00 PM CDT
    Session:
    Gastrointestinal Cancer—Colorectal and Anal
    Type:
    Poster Session
    Presenting Author:
    Ibrahim Halil Sahin
    Poster Board Number #:
    307A
    Download the poster
    Myeloablative fractionated busulfan conditioning regimen with sorafenib for allogeneic stem cell transplant in AML: Results of a phase 1/2 study
    Date/Time:
    Sunday, June 1, 2025 | 9:00 AM – 12:00 PM CDT
    Session:
    Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
    Type:
    Poster Session
    Presenting Author:
    Uday Popat
    Poster Board Number #:
    177
    Download the poster
    Combined RAF- and MEK-inhibition in solid cancers with kinase-impaired BRAF mutations (SORATRAM phase I trial)
    Date/Time:
    Monday June 2, 2025 | 1:30 PM – 4:30 PM CDT
    Session:
    Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
    Type:
    Poster Session
    Presenting Author:
    Anna Lena Illert
    Poster Board Number #:
    434
    Download the poster
    Evaluation of longitudinal image-derived AI prognostication as a predictor of overall survival (OS) in a phase 3 advanced non-small cell lung cancer (aNSCLC) trial
    Date/Time:
    Sunday, June 1, 2025 | 9:00 AM – 12:00 PM CDT
    Session:
    Care Delivery/Models of Care
    Type:
    Poster Session
    Presenting Author:
    Omar Farooq Khan
    Poster Board Number #:
    318
    Download the poster
    BAY 2927088

    BAY 2927088

    SOHO-01: Safety and efficacy of BAY 2927088 in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC) who were pretreated but naïve to HER2-targeted therapy or had not received any treatment for advanced disease
    Date/Time:
    Sunday, June 1, 2025 | 9:12 AM – 9:24 AM CDT
    Session:
    Lung Cancer—Non-Small Cell Metastatic
    Session Type:
    Oral Abstract Session
    Presenting Author:
    Herbert H. Loong
    Abstract Number #:
    8504
    Download the presentation
    panSOHO: Phase II trial of BAY 2927088 in patients with unresectable or metastatic solid tumors other than NSCLC with HER2‑activating mutations
    Date/Time:
    Monday, June 2, 2025 | 1:30 PM – 4:30 PM CDT
    Session:
    Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
    Type:
    Poster Session
    Presenting Author:
    Vivek Subbiah
    Poster Board Number #:
    486A
    Download the poster
    SOHO-02: Phase III trial of BAY 2927088 in patients with locally advanced or metastatic NSCLC with HER2-activating mutations.
    Date/Time:
    Saturday, May 31, 2025 | 1:30 PM – 4:30 PM CDT
    Session:
    Lung Cancer—Non-Small Cell Metastatic
    Type:
    Poster Session
    Presenting Author:
    Xiuning Le
    Poster Board Number #:
    127B
    Download the poster

     

    The compendium provided by Bayer is a compilation of Bayer sponsored presentations. Copies of presentations obtained from this compendium are for personal use only and may not be reproduced or distributed without permission from The American Society of Clinical Oncology (ASCO) and from the authors. The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities
    Reused with permission. © 2025 The American Society of Clinical Oncology (ASCO). All rights reserved.
    For any questions, please contact Medical Information at 1-888-84-BAYER (1-888-842-2937), or visit https://www.medicalinformation.bayer.com
    © 2025 Bayer. All rights reserved. Bayer and the Bayer Cross are registered trademarks of Bayer. 100 Bayer Boulevard, PO Box 915, Whippany, NJ 07981 USA. 5/25

    MA-BY-US-0045-1

    The compendium provided by Bayer is a compilation of Bayer sponsored presentations. Copies of presentations obtained from this compendium are for personal use only and may not be reproduced or distributed without permission from The American Society of Clinical Oncology (ASCO) and from the authors. The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities
    Reused with permission. © 2025 The American Society of Clinical Oncology (ASCO). All rights reserved.
    For any questions, please contact Medical Information at 1-888-84-BAYER (1-888-842-2937), or visit https://www.medicalinformation.bayer.com
    © 2025 Bayer. All rights reserved. Bayer and the Bayer Cross are registered trademarks of Bayer. 100 Bayer Boulevard, PO Box 915, Whippany, NJ 07981 USA. 5/25

    MA-BY-US-0046-1

    © 2023 Bayer. All rights reserved.
    Bayer and the Bayer Cross are registered trademarks of Bayer.
    MA-M_DAR-US-0203-1
    3/23

    © 2023 Bayer. All rights reserved.
    Bayer and the Bayer Cross are registered trademarks of Bayer.
    MA-M_DAR-US-0204-1
    3/23